keyword
MENU ▼
Read by QxMD icon Read
search

Dotation

keyword
https://www.readbyqxmd.com/read/28609356/the-north-american-neuroendocrine-tumor-society-consensus-guidelines-for-surveillance-and-medical-management-of-midgut-neuroendocrine-tumors
#1
Jonathan R Strosberg, Thorvardur R Halfdanarson, Andrew M Bellizzi, Jennifer A Chan, Joseph S Dillon, Anthony P Heaney, Pamela L Kunz, Thomas M O'Dorisio, Riad Salem, Eva Segelov, James R Howe, Rodney F Pommier, Kari Brendtro, Mohammad A Bashir, Simron Singh, Michael C Soulen, Laura Tang, Jerome S Zacks, James C Yao, Emily K Bergsland
There have been significant developments in diagnostic and therapeutic options for patients with neuroendocrine tumors (NETs). Key phase 3 studies include the CLARINET trial, which evaluated lanreotide in patients with nonfunctioning enteropancreatic NETs; the RADIANT-2 and RADIANT-4 studies, which evaluated everolimus in functioning and nonfunctioning NETs of the gastrointestinal tract and lungs; the TELESTAR study, which evaluated telotristat ethyl in patients with refractory carcinoid syndrome; and the NETTER-1 trial, which evaluated Lu-DOTATATE in NETs of the small intestine and proximal colon (midgut)...
July 2017: Pancreas
https://www.readbyqxmd.com/read/28588150/dose-mapping-after-endoradiotherapy-with-177-lu-dotatate-toc-by-one-single-measurement-after-four-days
#2
Heribert Hänscheid, Constantin Lapa, Andreas K Buck, Michael Lassmann, Rudolf A Werner
Dosimetry of organs and tumors helps to assess risks and benefit of treatment with (177)Lu-DOTATATE/ TOC. However, it is often not performed in clinical routine because of additional efforts, the complexity of data collection and analysis, and the additional burden for the patients. Aiming at a simplification of dosimetry, we analyzed the accuracy of a theoretically substantiated approximation, which allows to calculate absorbed doses from a single measurement of the abdominal activity distribution. Methods: Activity kinetics were retrospectively assessed from planar images in 29 patients with neuroendocrine tumors (NET, n = 21) or meningioma (n = 8) after the administration of (177)Lu-DOTATATE (n = 22) or (177)Lu-DOTATOC (n = 7)...
June 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28553179/peptide-receptor-radionuclide-therapy-with-177-lu-dotatate-for-metastatic-neuroendocrine-tumor-occurring-in-association-with-multiple-endocrine-neoplasia-type-1-and-cushing-s-syndrome
#3
Chinna Naik, Sandip Basu
Neuroendocrine tumor (NET) occurring in association with other endocrine syndromes forms a distinct entity. The aim was to assess the therapy response profile of the routine peptide receptor radionuclide therapy (PRRT) in this relatively uncommon but clinically challenging subgroup of patients. A retrospective analysis was undertaken from the case records from those who were treated with (177)Lu-DOTATATE for metastatic NET. In addition to assessing the therapeutic efficacy, emphasis was also given to study lesional sites and scan pattern...
April 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28542563/evaluation-of-somatostatin-and-nucleolin-receptors-for-therapeutic-delivery-in-non-small-cell-lung-cancer-stem-cells-applying-the-somatostatin-analog-dotatate-and-the-nucleolin-targeting-aptamer-as1411
#4
Sif Holmboe, Pernille Lund Hansen, Helge Thisgaard, Ines Block, Carolin Müller, Niels Langkjær, Poul Flemming Høilund-Carlsen, Birgitte Brinkmann Olsen, Jan Mollenhauer
Cancer stem cells represent the putative tumor-driving subpopulation thought to account for drug resistance, relapse, and metastatic spread of epithelial and other cancer types. Accordingly, cell surface markers for therapeutic delivery to cancer stem cells are subject of intense research. Somatostatin receptor 2 and nucleolin are known to be overexpressed by various cancer types, which have elicited comprehensive efforts to explore their therapeutic utilization. Here, we evaluated somatostatin receptor 2 targeting and nucleolin targeting for therapeutic delivery to cancer stem cells from lung cancer...
2017: PloS One
https://www.readbyqxmd.com/read/28533641/image-findings-of-a-rare-case-of-neuroendocrine-tumor-metastatic-to-orbital-extraocular-muscle-in-gallium-68-dotanoc-positron-emission-tomography-computed-tomography-and-therapy-with-lutetium-177-dotatate
#5
Koramadai Karuppusamy Kamaleshwaran, Jephy Joseph, Indra Upadhya, Ajit Sugunan Shinto
Metastatic tumor is one of several etiologies of space-occupying masses in the orbit that accounts for 1-13% of all orbital masses. In the adult patient population, breast cancer is the most common tumor to metastasize to the orbit, followed by metastasis from the lung, prostate, and gastrointestinal tract. Carcinoid tumors are rare neuroendocrine neoplasms derived from enterochromaffin cells, which are found primarily in the gastrointestinal tract and bronchial tree. Liver metastases are the classic presentation of distant disease...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28533634/estimation-of-whole-body-radiation-exposure-to-nuclear-medicine-personnel-during-synthesis-of-177-lutetium-labeled-radiopharmaceuticals
#6
Geetanjali Arora, Rajesh Mishra, Praveen Kumar, Madhav Yadav, Sanjana Ballal, Chandrasekhar Bal, Nishikant Avinash Damle
PURPOSE OF THE STUDY: With rapid development in the field of nuclear medicine therapy, radiation safety of the personnel involved in synthesis of radiopharmaceuticals has become imperative. Few studies have been done on estimating the radiation exposure of personnel involved in the radio labeling of (177)Lu-compounds in western countries. However, data from the Indian subcontinent are limited. We have estimated whole body radiation exposure to the radiopharmacist involved in the labeling of: (177)Lu-DOTATATE, (177)Lu-PSMA-617, and (177)Lu-EDTMP...
April 2017: Indian Journal of Nuclear Medicine: IJNM: the Official Journal of the Society of Nuclear Medicine, India
https://www.readbyqxmd.com/read/28473600/most-intended-management-changes-after-68-ga-dotatate-pet-ct-are-implemented
#7
Jérémie Calais, Johannes Czernin, Matthias Eiber, Wolfgang Peter Fendler, Jeannine Gartmann, Anthony Heaney, Andrew Hendifar, Joseph Pisegna, Joel Randolph Hecht, Edward Wolin, Roger Slavik, Pawan Gupta, Andrew Quon, Christiaan Schiepers, Martin Allen-Auerbach, Ken Herrmann
Background: In this prospective referring physician based survey, we investigated the definite clinical impact of (68)Ga-DOTATATE positron emission tomography / computed tomography (PET/CT) on managing patients with neuroendocrine tumors (NET). Methods: We prospectively studied 130 patients with (68)Ga-DOTATATE PET/CT referred for initial or subsequent management decisions (NCT02174679). Referring physicians completed one questionnaire prior to the scan (Q1) to indicate the treatment plan without PET/CT information; one immediately after review of the imaging report to denote intended management changes (Q2); and one 6 months later (Q3) to verify whether intended changes were in fact implemented...
May 4, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28471845/early-efficacy-of-and-toxicity-from-lutetium-177-dotatate-treatment-in-patients-with-progressive-metastatic-net
#8
Deborah Pencharz, Martin Walker, Mehmet Yalchin, Ann-Marie Quigley, Martyn Caplin, Christos Toumpanakis, Shaunak Navalkissoor
OBJECTIVE: Lutetium-177 DOTA-D-Phe1-Tyr3-octreotide (Lu-DOTATATE) is a treatment option for patients with well-differentiated metastatic neuroendocrine tumours. Our centre started administering this therapy in 2012. The aim of this study was therefore to analyse the first cohort of patients treated with Lu-DOTATATE to determine its early efficacy and toxicity. PATIENTS AND METHODS: We retrospectively analysed patient, tumour and treatment characteristics, end-of-treatment outcome, time to progression and toxicity in 79 consecutive patients treated with Lu-DOTATATE who had progressive NET according to Response Evaluation Criteria in Solid Tumours criteria...
May 3, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28462171/multiple-recurrent-paraganglioma-in-a-pediatric-patient-with-germline-sdh-b-mutation
#9
Aidan McGowan, Julie Y An, Sally Tanakchi, Mahir Maruf, Akhil Muthigi, Arvin George, Daniel Su, Maria J Merino, W Marston Linehan, Shawna L Boyle, Adam R Metwalli
Magnetic Resonance Imaging (MRI) and fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) are recognized approaches for locating paragangliomas. Recently, gallium-68 DOTA-octreotate (DOTATATE) scans have shown promise detecting neuroendocrine tumors missed by FDG-PET and MRI. 13-year-old male with SDH-B mutation presented with symptoms of paraganglioma and elevated catecholamines. MRI did not demonstrate the T2 hyper intense signal typical of paraganglioma and pheochromocytoma; FDG-PET scan did not reveal increased foci of uptake...
July 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28450556/improved-detection-of-transosseous-meningiomas-using-68-ga-dotatate-pet-ct-compared-to-contrast-enhanced-mri
#10
Wolfgang G Kunz, Lisa M Jungblut, Philipp M Kazmierczak, Franziska J Vettermann, Andreas Bollenbacher, Jörg C Tonn, Christian Schichor, Axel Rominger, Nathalie L Albert, Peter Bartenstein, Maximilian F Reiser, Clemens C Cyran
(68)Ga-DOTATATE PET-CT enables detection of meningioma tissue based on somatostatin receptor 2 expression. Transosseous extension of intracranial meningiomas is known to be an important risk factor of tumor recurrence and patient mortality. We analyzed the diagnostic performance of (68)Ga-DOTATATE PET-CT and contrast-enhanced MRI (CE-MRI) for the detection of osseous infiltration using qualitative and quantitative imaging parameters. Methods: In this IRB-approved retrospective study, subjects were selected from 327 consecutive (68)Ga-DOTATATE PET-CT exams for evaluation of confirmed or suspected meningioma...
April 27, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28435455/the-netpet-score-combining-fdg-and-somatostatin-receptor-imaging-for-optimal-management-of-patients-with-metastatic-well-differentiated-neuroendocrine-tumors
#11
EDITORIAL
Elif Hindié
Neuroendocrine tumors (NET) are often metastatic at the time of diagnosis. Metastatic well-differentiated (G1/G2) NET may display a wide range of behaviors, ranging from indolent to aggressive, even within apparently homogeneous categories. Thus, selecting the optimal treatment strategy is a challenging task. Somatostatin receptor imaging (SRI) is the standard molecular imaging technique for well-differentiated NET. When performed with (68)Ga-labeled somatostatin analogs (SRI-PET), it offers exquisite sensitivity for disease staging...
2017: Theranostics
https://www.readbyqxmd.com/read/28433399/simultaneous-68-ga-dotatate-positron-emission-tomography-magnetic-resonance-imaging-in-meningioma-target-contouring-feasibility-and-impact-upon-interobserver-variability-versus-positron-emission-tomography-computed-tomography-and-computed-tomography-magnetic
#12
J Maclean, N Fersht, K Sullivan, I Kayani, J Bomanji, J Dickson, C O'Meara, S Short
AIMS: The increasing use of highly conformal radiation techniques to treat meningioma confers a greater need for accurate targeting. Several groups have shown that positron emission tomography/computed tomography (PET/CT) information alters meningioma targets contoured by single observers, but whether this translates into improved accuracy has not been defined. As magnetic resonance imaging (MRI) is the cornerstone of meningioma target contouring, simultaneous PET/MRI may be superior to PET/CT...
July 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/28429044/-68-ga-dotatate-pet-ct-in-recurrent-medullary-thyroid-carcinoma-a-lesion-by-lesion-comparison-with-111-in-octreotide-spect-ct-and-conventional-imaging
#13
Lilian Yuri Itaya Yamaga, Marcelo L Cunha, Guilherme C Campos Neto, Marcio R T Garcia, Ji H Yang, Cleber P Camacho, Jairo Wagner, Marcelo B G Funari
PURPOSE: The aim of this study was to prospectively compare the detection rate of (68)Ga-DOTATATE PET-CT with (111)In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy. METHODS: Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent (68)Ga-DOTATATE PET-CT, (111)In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard...
April 20, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28428192/long-term-efficacy-survival-and-safety-of-177-lu-dota-0-tyr-3-octreotate-in-patients-with-gastroenteropancreatic-and-bronchial-neuroendocrine-tumors
#14
Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Richard A Feelders, Wouter W de Herder, Casper H J van Eijck, Gaston J H Franssen, Eric P Krenning, Dik J Kwekkeboom
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177-labeled somatostatin analogues. We have treated over 1,200 patients with peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) since the year 2000 and present the results on efficacy, survival, and toxicity of this therapy.Experimental Design: For safety analysis, 610 patients treated with a cumulative dose of at least 100 mCi (3...
April 20, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28400403/molecular-imaging-in-the-investigation-of-hypoglycaemic-syndromes-and-their-management
#15
David A Pattison, Rodney J Hicks
There has been recent progress in molecular imaging using a variety of cellular targets for the investigation of adult non-diabetic hypoglycaemic syndromes and its integration into patient management. These targets include peptide receptors - somatostatin receptors (SSTR) and glucagon-like peptide-1 receptor (GLP-1R) - the Amine Precursor Uptake and Decarboxylation system utilising the diphydroxyphenylaline (DOPA) analogue 6-[18F]-L-fluoro-L-3, 4-dihydroxyphenylalanine (18F-FDOPA), and glycolytic metabolism with 2-[18F]Fluoro-2-Deoxy-D-Glucose (FDG)...
April 11, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28385306/detection-of-atherosclerotic-inflammation-by-68-ga-dotatate-pet-compared-to-18-f-fdg-pet-imaging
#16
Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Mohammed M Chowdhury, Nichola L Figg, Aarti V Shah, Lakshi T Starks, Abel Martin-Garrido, Roido Manavaki, Emma Yu, Rhoda E Kuc, Luigi Grassi, Roman Kreuzhuber, Myrto A Kostadima, Mattia Frontini, Peter J Kirkpatrick, Patrick A Coughlin, Deepa Gopalan, Tim D Fryer, John R Buscombe, Ashley M Groves, Willem H Ouwehand, Martin R Bennett, Elizabeth A Warburton, Anthony P Davenport, James H F Rudd
BACKGROUND: Inflammation drives atherosclerotic plaque rupture. Although inflammation can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FDG lacks cell specificity, and coronary imaging is unreliable because of myocardial spillover. OBJECTIVES: This study tested the efficacy of gallium-68-labeled DOTATATE ((68)Ga-DOTATATE), a somatostatin receptor subtype-2 (SST2)-binding PET tracer, for imaging atherosclerotic inflammation...
April 11, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28379809/177lu-dotatate-for-midgut-neuroendocrine-tumors
#17
LETTER
Claude Matuchansky
No abstract text is available yet for this article.
April 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28379808/177lu-dotatate-for-midgut-neuroendocrine-tumors
#18
LETTER
Jonathan Strosberg, Eric Krenning
No abstract text is available yet for this article.
April 6, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28342392/value-of-the-68-ga-dotatate-pet-ct-in-the-diagnosis-of-endometriosis-a-pilot-study
#19
M Fastrez, C Artigas, N Sirtaine, Z Wimana, M Caillet, S Rozenberg, P Flamen
OBJECTIVE: The non-invasive diagnosis of endometriosis remains challenging. Recent data suggested that somatostatin might be involved in its pathogenesis. High sensitive visualization of somatostatin receptors expression is possible using PET-CT imaging after the administration of a (68)Ga-labeled somatostatin analog (DOTATATE) that will bind to the somatostatin receptor sub-types 2 and 5. The aim of the present study was to assess the usefulness of (68)Ga-DOTATATE PET-CT in the diagnosis of endometriosis...
May 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28341976/development-and-evaluation-of-user-friendly-single-vial-dota-peptide-kit-formulations-specifically-designed-for-radiolabelling-with-68-ga-from-a-tin-dioxide-68-ge-68-ga-generator
#20
Deidré Prince, Daniel Rossouw, Claudia Davids, Sietske Rubow
PURPOSE: This study was aimed to develop single vial 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-peptide kits to be used with fractionated eluates from a SnO2-based (68)Ge/(68)Ga generator. PROCEDURES: Kits were formulated with 35 μg DOTA-Tyr(3)-Thre(8)-octreotide, DOTA-[Tyr(3)]-octreotide and DOTA-[NaI(3)]-octreotide (DOTATATE, DOTATOC and DOTANOC) and sodium acetate powder, vacuum-dried and stored at -20 °C for up to 12 months. Labelling of the kits was carried out with 2 ml (68)Ga eluate...
March 24, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
keyword
keyword
96892
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"